Department of Obstetrics and Gynecology, Makerere University College of Health Sciences, Kampala, Uganda.
Department of Obstetrics and Gynecology, Makerere University College of Health Sciences, Kampala, Uganda.
Lancet Glob Health. 2022 Oct;10(10):e1505-e1513. doi: 10.1016/S2214-109X(22)00312-6. Epub 2022 Aug 26.
To address the knowledge gaps in the provision of post-abortion care by midwives for women in the second trimester, we investigated the effectiveness and safety of treatment for incomplete second trimester abortion with misoprostol, comparing care provision by midwives with that provided by physicians in Uganda.
Our multicentre, randomised, controlled, equivalence trial undertaken in 14 health facilities in Uganda recruited women with incomplete abortion of uterine size 13-18 weeks. We randomly assigned (1:1) women to clinical assessment and treatment by either midwife or physician. The randomisation sequence was computer generated, in blocks of four to 12, and stratified for study site. Participants received sublingual misoprostol (400 μg once every 3 h for up to five doses). The study was not concealed from the health-care providers and study participants. Primary outcome was complete abortion within 24 h that did not require surgical evacuation. Analysis was per-protocol and intention to treat; the intention-to-treat population consisted of women who were randomised, received at least one dose of misoprostol, and reported primary outcome data, and the per-protocol population excluded women with unexplained discontinuation of treatment. We used generalised mixed-effects models to obtain the risk difference. The predefined equivalence range was -5% to 5%. The trial was registered at ClinicalTrials.gov, NCT03622073.
Between Aug 14, 2018, and Nov 16, 2021, 1191 eligible women were randomly assigned to each group (593 women to the midwife group and 598 to the physician group). 1164 women were included in the per-protocol analysis, and 530 (92%) of 577 women in the midwife group and 553 (94%) of 587 women in the physician group had a complete abortion within 24 h. The model-based risk difference for the midwife versus physician group was -2·3% (95% CI -4·4 to -0·3), and within our predefined equivalence range (-5% to 5%). Two women in the midwife group received blood transfusion.
Clinical assessment and treatment of second trimester incomplete abortion with misoprostol provided by midwives was equally effective and safe as when provided by physicians. In low-income settings, inclusion of midwives in the medical management of uncomplicated second trimester incomplete abortion has potential to increase women's access to safe post-abortion care.
Swedish Research Council and THRiVE-2.
为了填补助产士在为妊娠中期妇女提供堕胎后护理方面的知识空白,我们调查了米索前列醇治疗妊娠中期不完全流产的效果和安全性,并将助产士提供的护理与乌干达医生提供的护理进行了比较。
我们在乌干达的 14 家医疗机构进行了这项多中心、随机、对照、等效性试验,招募了子宫大小为 13-18 周的不完全流产的妇女。我们将妇女随机分配(1:1),由助产士或医生进行临床评估和治疗。随机序列是使用计算机生成的,块大小为 4 至 12,按研究地点分层。参与者接受舌下含服米索前列醇(400 μg 每 3 小时一次,最多 5 剂)。该研究对医疗保健提供者和研究参与者均不设盲。主要结局是 24 小时内无需手术清除的完全流产。分析采用方案和意向治疗;意向治疗人群包括随机分配、至少接受一剂米索前列醇且报告主要结局数据的妇女,排除了未解释治疗中断的妇女。我们使用广义混合效应模型获得风险差异。预设的等效范围为-5%至 5%。该试验在 ClinicalTrials.gov 注册,NCT03622073。
2018 年 8 月 14 日至 2021 年 11 月 16 日,符合条件的 1191 名妇女被随机分配到每组(593 名妇女分到助产士组,598 名妇女分到医生组)。1164 名妇女纳入方案分析,577 名妇女中 530 名(92%)和 587 名妇女中 553 名(94%)在 24 小时内完全流产。基于模型的助产士组与医生组的风险差异为-2.3%(95%CI-4.4 至-0.3),在我们预设的等效范围内(-5%至 5%)。助产士组中有 2 名妇女接受了输血。
由助产士进行米索前列醇治疗妊娠中期不完全流产的临床评估和治疗与由医生进行的治疗同样有效且安全。在低收入环境中,将助产士纳入妊娠中期不完全流产的常规医疗管理,有可能增加妇女获得安全堕胎后护理的机会。
瑞典研究理事会和 THRIVE-2。